UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE
14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
| Filed by the Registrant x | Filed by a Party other than the Registrant ¨ |
Check the appropriate box:
| ¨ | Preliminary Proxy Statement |
| ¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ¨ | Definitive Proxy Statement |
| x | Definitive Additional Materials |
| ¨ | Soliciting Material Pursuant to sec. 240.14a-12 |
NEUBASE THERAPEUTICS, INC.
(Name of Registrant as Specified In Its
Charter)
N/A
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| x | No fee required. |
| ¨ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
| (1) | Title of each class of securities to which transaction applies: |
| (2) | Aggregate number of securities to which transaction applies: |
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): |
| (4) | Proposed maximum aggregate value of transaction: |
| (5) | Total fee paid: |
| ¨ | Fee paid previously with preliminary materials. |
| ¨ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
| (1) | Amount Previously Paid: |
| (2) | Form, Schedule or Registration State No.: |
| (3) | Filing Party: |
| (4) | Date Filed: |
NeuBase Therapeutics, Inc. Important Notice Regarding the Availability of Proxy Materials for the NeuBase Therapeutics, Inc. Annual Meeting of Stockholders to be held on August 12, 2020 This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the proxy statement and annual report, go to www.proxydocs.com/NBSE. To submit your proxy while visiting this site, you will need the 12 digit control number in the shaded gray box below.Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. We have chosen to use these procedures for our 2020 Annual Meeting and need YOUR participation.If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s annual meeting, please make this request on or before July 31, 2020.For a convenient way to VIEW Proxy Materials _ and _ VOTE online go to: www.proxydocs.com/NBSEProxy Materials Available to View or Receive: 1. Notice and Proxy Statement 2. Annual Report Printed materials may be requested by one of the following methods:INTERNET www.investorelections.com/NBSETELEPHONE (866) 648-8133*E-MAIL paper@investorelections.comYou must use the 12 digit control number located in the shaded gray box below.* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting material.ACCOUNT NO. SHARESNeuBase Therapeutics, Inc. Notice of Annual Meeting of StockholdersDate: Time: Registration and Access:Wednesday, August 12, 2020 10:00 a.m. Eastern Time Register by August 10, 2020 at 5 p.m. Eastern Time at www.proxydocs.com/NBSE and follow instructionsThe purpose of the Annual Meeting is to take action on the following proposals: The Board of Directors recommends a vote FOR the election of the nominee for the director named below, FOR Proposal Nos. 2 and 3 and ONE YEAR for Proposal No. 4. 1. To elect one Class III Director, Franklyn G. Prendergast, Ph.D., nominated by our Board of Directors, to serve until our 2023 Annual Meeting of Stockholders and until his successor is duly elected and qualified. 2. To ratify the selection of Marcum LLP as our independent registered public accounting firm for the fiscal year ending September 30, 2020. 3. To approve, on an advisory basis, the compensation paid to the Company’s Named Executive Officers, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion within the section of the Company’s Proxy Statement entitled “Executive Compensation.” 4. To approve, on an advisory basis, the frequency of holding future advisory votes on executive compensation.